Clinical Trials

Pancreatic Neoplasms

NCT02890355 2026-03-05

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

123 enrolled 15 charts

Pancreatic Neoplasms

NCT04683315 2026-03-05

PANCREAS

84 enrolled

Pancreatic Neoplasms

NCT02021422 2026-02-18

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Phase 1 Completed

13 enrolled

Phase 3 Active not recruiting

Pancreatic Neoplasms

NCT04340141 2026-02-10

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

358 enrolled

Pancreatic Neoplasms

NCT07214298 2026-02-06

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

35 enrolled

Pancreatic Neoplasms

NCT06381154 2026-01-30

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

25 enrolled

Pancreatic Neoplasms

NCT04421820 2026-01-27

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Phase 1/2 Recruiting

220 enrolled

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03977233 2026-01-13

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

45 enrolled

Phase NA Not yet recruiting

Pancreatic cancer, adult, Pancreatic Neoplasms

NCT07325214 2026-01-12

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

136 enrolled

Pancreatic Neoplasms

NCT03322995 2026-01-08

PANC

125 enrolled

Pancreatic Neoplasms

NCT03443492 2025-12-30

Pancreas

Phase 2 Completed

130 enrolled

Pancreatic Neoplasms

NCT04390399 2025-12-15

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

328 enrolled

Phase 3 Active not recruiting

Pancreatic Neoplasms

NCT06385925 2025-12-15

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Phase 1/2 Recruiting

440 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06625320 2025-12-12

RASolute 302

501 enrolled

Pancreatic Neoplasms

NCT06941857 2025-12-03

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

20 enrolled

Phase 3 Not yet recruiting

Carcinoma, Pancreatic Neoplasms

NCT07262567 2025-12-03

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

320 enrolled

Pancreatic Neoplasms

NCT05417386 2025-11-18

FOLFIRINOX + NIS793 in Pancreatic Cancer

Phase 1 Terminated

4 enrolled

Pancreatic Neoplasms

NCT01489865 2025-11-06

ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

64 enrolled 20 charts

Phase 1/2 Active not recruiting

Pancreatic Neoplasms

NCT04821284 2025-11-04

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

120 enrolled

Pancreatic Neoplasms

NCT03184870 2025-10-09

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

332 enrolled 44 charts

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03724994 2025-08-29

CHAMP

Completed

201 enrolled

Pancreatic Neoplasms

NCT04141995 2025-08-07

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

Phase 2 Terminated

11 enrolled

Pancreatic Neoplasms

NCT04594772 2025-07-02

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

32 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT03073785 2025-05-25

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

46 enrolled

Pancreatic Neoplasms

NCT06897644 2025-05-25

PANThEON

Phase 3 Recruiting

340 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT03750669 2025-05-13

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Phase 3 Completed

324 enrolled

Phase EARLY_PHASE1 Completed

Pancreatic Neoplasms

NCT02896907 2025-04-30

Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

8 enrolled 9 charts

Pancreatic Neoplasms

NCT03563144 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Phase 2 Withdrawn

Pancreatic Neoplasms

NCT03822936 2025-02-13

PIOPPO

Phase 2 Terminated

30 enrolled

Pancreatic Neoplasms

NCT06538207 2025-02-06

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Phase 1 Completed

46 enrolled

Pancreatic Neoplasms

NCT03699319 2025-01-23

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Phase 1/2 Completed

49 enrolled

Phase EARLY_PHASE1 Completed

Pancreatic Neoplasms

NCT01821612 2025-01-13

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

23 enrolled

Pancreatic Neoplasms

NCT04164069 2024-12-27

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Phase 1 Completed

9 enrolled